CAJ | 학술논문

目的探讨尼卡地平抑制肝癌耐药细胞增殖的机制。方法采用同位素掺入法研究细胞的增殖，荧光分光光度法测定细胞内抗癌药物浓度。结果单独应用尼卡地平(NIC)对耐药肝癌细胞BEL-7402/ADR有不同程度的抑制作用；而对细胞增殖基本无影响的2.5μg*ml-1浓度的NIC与阿霉素(ADR)合用时，半数抑制量(IC50)较单独用ADR时明显降低(P<0.05)；与5.0μg*ml-1的NIC合用时，其IC50较单独用ADR降低更显著(P<0.01)。NIC可显著增加细胞内的抗癌药浓度(P<0.05～0.01)。结论 NIC降低ADR的IC50，增加抗癌药的细胞毒性，可能与其拮抗P170糖蛋白有关。
목적탐토니잡지평억제간암내약세포증식적궤제。방법채용동위소참입법연구세포적증식，형광분광광도법측정세포내항암약물농도。결과단독응용니잡지평(NIC)대내약간암세포BEL-7402/ADR유불동정도적억제작용；이대세포증식기본무영향적2.5μg*ml-1농도적NIC여아매소(ADR)합용시，반수억제량(IC50)교단독용ADR시명현강저(P<0.05)；여5.0μg*ml-1적NIC합용시，기IC50교단독용ADR강저경현저(P<0.01)。NIC가현저증가세포내적항암약농도(P<0.05～0.01)。결론 NIC강저ADR적IC50，증가항암약적세포독성，가능여기길항P170당단백유관。
Objective　To investigate the mechanism through which nicardipine (NIC) suppress the proliferation of drug-resistant liver cancer cells.Method　Cellular proliferation were studied by isotope labeling technique，and the concentrations of intracellular anticancer drugs were measured by fluorospectrophotometry.Results　Nicardipine alone exhibited different degree of suppressive effects on drug-resistant liver cancer cells,BEL-7402/ADR.While adriamycin(ADR) in combination with NIC at the concentration of 2.5μg*ml-1,IC50 were significantly reduced(P<0.05) when compared with ADR alone.When the concentration of rosed to NIC 5.0μg*ml-1，IC50 were more significantly reduced(P<0.01).The results also showed that NIC evidently increased the concentration of intracellular anticancer drugs.Conclusion　NIC can both reduce the IC50 of ADR and increase the cytotoxicitry of anticancer drugs.This action may be related to its antagonizing P170 glocoprotein.